Neurogene's NGN-401 Receives FDA Breakthrough Designation for Rett Syndrome
The FDA granted Breakthrough Therapy designation to NGN-401, Neurogene's gene therapy for Rett syndrome, based on interim data showing durable functional improvements. The company expects to complete pivotal trial dosing in Q2 2026.
On February 26, 2026, Neurogene announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to NGN-401, its late-stage investigational AAV9 gene therapy for Rett syndrome. The decision was based on interim Phase 1/2 data through October 30, 2025, showing clinically meaningful, durable and multidomain functional improvements with continued skill acquisition, and a generally well-tolerated safety profile at the 1E15 vg dose.
NGN-401 uniquely delivers the full-length human MECP2 gene using Neurogene's EXACT transgene regulation technology via intracerebroventricular administration. The therapy is being studied in the Embolden registrational trial, where dosing is expected to be completed in the second quarter of 2026. Dosing began in the fourth quarter of 2025, and the company has disclosed that multiple patients have been dosed.
Neurogene expects to present updated Phase I/II results in the middle of 2026 across 10 dosed patients with at least 12 months of follow-up. Phase I/II data presented last year in eight participants showed 35 milestones gained across the group—about four skills per patient on average. The improvements were characterized as multi-domain, durable, and continuing to deepen over time.
Rett syndrome is a devastating neurologic disease that primarily affects girls. Children often show developmental delays before losing previously acquired milestones around 18 months to 2–3 years of age, followed by a period of relative stability marked by profound impairments in hand use, communication, and gross motor function.
The therapy's design reflects three priorities: delivering the therapy to the key areas of the brain implicated in Rett syndrome, using a construct that encodes the full-length human MECP2 gene intended to ensure translation of functional protein, and constraining and regulating transgene expression because MECP2 has a very narrow therapeutic window and is highly toxic when overexpressed. The expression-regulation technology is attributed to work by Stuart Cobb and his team at Edinburgh and is described as proprietary to Neurogene.
Regarding safety, the company had seen hemophagocytic lymphohistiocytosis (HLH) at a 3E15 dose and is now operating at a 1E15 dose in the pivotal study. The 1E15 dose is three times lower than the dose where HLH occurred. Neurogene added ferritin to its standard immune monitoring labs and is tracking key criteria including hyperferritinemia, cytopenia, and fever. HLH can be fully reversible if detected early, typically managed with steroids as first-line treatment and anakinra (an IL-1 agent) as a potential second-line option. The company has dosed more than 10 patients at the 1E15 level without needing to intervene.
An abnormal nerve conduction finding was reported in one patient. The finding was transient and the patient later returned to a normal nerve conduction range. Neuropathy was characterized as a potential class effect risk with AAV gene therapies, with observations across other programs and routes of administration.
The new designation adds to a suite of U.S., European and U.K. regulatory recognitions and is poised to expedite development and review, potentially strengthening Neurogene's competitive position in Rett syndrome therapies and offering stakeholders a clearer regulatory path toward possible approval.